The sweet and bitter sides of galectins in melanoma progression. - Wikidata - awgldk - TriplyDB

The sweet and bitter sides of galectins in melanoma progression.

The sweet and bitter sides of galectins in melanoma progression.

http://www.wikidata.org/entity/Q38016538

about

Nuclear transport of galectin-3 and its therapeutic implications IDO and galectin-3 hamper the ex vivo generation of clinical grade tumor-specific T cells for adoptive cell therapy in metastatic melanoma Melanocytic galectin-3 is associated with tyrosinase-related protein-1 and pigment biosynthesis.Gene silencing of galectin-3 changes the biological behavior of Eca109 human esophageal cancer cells.Fully phosphorothioate-modified CpG ODN with PolyG motif inhibits the adhesion of B16 melanoma cells in vitro and tumorigenesis in vivo Melanoma stem cells and metastasis: mimicking hematopoietic cell trafficking?Melanoma biomolecules: independently identified but functionally intertwined.Why is melanoma so metastatic?The involvement of CD146 and its novel ligand Galectin-1 in apoptotic regulation of endothelial cells.Galectin-1 inhibitors and their potential therapeutic applications: a patent review.Effect of galectin-3 on the behavior of Eca‑109 human esophageal cancer cells.Melanoma Cell Galectin-1 Ligands Functionally Correlate with Malignant Potential Combined Anti-VEGF and Anti-CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes.Pattern of galectins expression in actinic cheilitis with different risks of malignant transformation.RETRACTED: Effect of galectin-3 on vasculogenic mimicry in esophageal cancer cells.The Role of Galectins in Cervical Cancer Biology and Progression.

P2860

Q26824889-BC996934-8D07-450D-A614-E89B5AAFB1CC Q33849567-30FAB6BA-B253-4585-9BD6-7FD31220A045 Q34718290-6FEFDB1C-84BB-4FC2-800E-0D423795F759 Q36390226-4CE4AABE-A629-4893-BD58-BB2E7A949434 Q37044950-AB6617BF-A9EC-4034-A5D5-9394AE5F0662 Q37615286-92FCCFFF-803B-4E47-A61D-E99C6F649E55 Q38143977-DC363084-694D-444D-989D-B73D4C2E23D9 Q38150869-E967C226-43DB-4229-96B6-14EE94397C21 Q38319415-5BBD4BB1-07D8-42A0-9334-46287B5DD9D3 Q38763827-9959E6AB-2C69-431F-B4F8-DFAA16758ED9 Q38942488-743C6C8A-C834-4A84-868C-AAEF414B7F66 Q41780259-7CA04389-B133-4A34-A1C8-6AA14905D3DD Q51019599-14552917-3873-4F5D-9A20-E57D959FFF48 Q53208686-CD7233F8-8B15-4954-A017-862D72ED45C1 Q53431665-B66B0A29-C15C-4C00-8B01-6B2133B24EBD Q55152503-860AAEF5-86C7-4829-A807-2A77A6EF3CA2

P2860

The sweet and bitter sides of galectins in melanoma progression.

http://www.wikidata.org/entity/Q38016538

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

The sweet and bitter sides of galectins in melanoma progression.

@en

type

label

The sweet and bitter sides of galectins in melanoma progression.

@en

prefLabel

The sweet and bitter sides of galectins in melanoma progression.

@en

P1433

Q38016538-09A4D1D5-66F9-48F2-8F9F-11628A34E1D0

P1476

Q38016538-64661352-900D-4365-AB4C-2C44D93AA706

P2093

Q38016538-234C28CE-21A2-444D-A532-1062971B7B90

Q38016538-50117290-7EA9-4559-B528-7C2EC506B0F8

Q38016538-8435AE9E-4045-4899-9A96-27F0AFC0E5DF

Q38016538-EF74AB8D-6E6B-4B06-89C3-2A381B7EED2D

P2860

Q38016538-061EF9A1-537A-4CDE-BA44-EF61C2217742

Q38016538-070A89DF-368A-490F-84CF-B7EDDFF0D9F1

Q38016538-07DBCBDF-C9F6-450E-B91A-BB4FE0209584

Q38016538-0969E363-D19C-4F12-9926-F0E6469189D7

Q38016538-0DE02640-A713-49D2-834D-14DC8B56727E

Q38016538-0EEC013D-5577-4F2E-AA99-4EDF9227644E

Q38016538-12EC9F90-0E7F-4477-82EF-253A6DE80ABE

Q38016538-16B9ACB8-0BEF-4D3A-A0EA-AAD8B7B74897

Q38016538-1AE7E070-C3ED-43A9-8FDE-1F8460E3F82C

Q38016538-1DABF1A4-B77D-4403-8238-2C4FBBE45BAD

P304

Q38016538-A8BC4E0B-DB7C-434C-B1DA-12AE72B45A1A

P31

Q38016538-0E0E8AA2-3F6E-4880-B0DC-5AEBFE7CAF73

P356

Q38016538-E3F21EA0-CC1E-43C8-9254-8CAC7D47EE4C

P433

Q38016538-FC73743F-5DB6-44A8-B0EE-936F51163262

P478

Q38016538-2D72179D-BDCB-4D69-BE26-C0232C8988D5

P577

Q38016538-BF9B7292-CF73-46BD-873F-D46E9EA648FA

P698

Q38016538-E41BB262-FF6D-40EA-9D8A-2D36200925A8

P356

J.1755-148X.2012.01026.X

P1433

Pigment Cell & Melanoma Research

P1476

The sweet and bitter sides of galectins in melanoma progression.

@en

P2093

Einav Shoshan

http://www.w3.org/2001/XMLSchema#string

Menashe Bar-Eli

http://www.w3.org/2001/XMLSchema#string

Russell R Braeuer

http://www.w3.org/2001/XMLSchema#string

Takafumi Kamiya

http://www.w3.org/2001/XMLSchema#string

P2860

Galectin-3 regulates MUC1 and EGFR cellular distribution and EGFR downstream pathways in pancreatic cancer cells

Association of galectin-1 and galectin-3 with Gemin4 in complexes containing the SMN protein

NG2 proteoglycan promotes endothelial cell motility and angiogenesis via engagement of galectin-3 and alpha3beta1 integrin

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

Galectin-1 research in T cell immunity: past, present and future

Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.

Cancer statistics, 2012

Glycoprotein 90K/MAC-2BP interacts with galectin-1 and mediates galectin-1-induced cell aggregation

Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria. A role for synexin in galectin-3 translocation

Possible role of galectin-9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance

P304

592-601

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1755-148X.2012.01026.X

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2012-07-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22672152

http://www.w3.org/2001/XMLSchema#string